You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

243 Results
Regimen
Cancer Type:
Gynecologic, 
Ovary
Intent: Adjuvant
Nov 2021
Regimen
Cancer Type:
Sarcoma, 
Ewing's
Intent: Palliative
Funding:
ODB - General Benefit
    temozolomide
Aug 2021
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Hodgkin
Intent: Palliative
May 2019
Regimen
Cancer Type:
Hematologic, 
Rare Diseases
Intent: Curative
Funding:
ODB - General Benefit
    prednisone
May 2019
Regimen
Cancer Type:
Genitourinary, 
Prostate
Intent: Palliative
Funding:
ODB - General Benefit
    cyclophosphamide - oral tablets
May 2019
Regimen
Cancer Type:
Gynecologic, 
Germ Cell
Intent: Curative
Mar 2021
Regimen
Regimen
Cancer Type:
Gynecologic, 
Cervix
Intent: Neoadjuvant
May 2019
Regimen
Cancer Type:
Hematologic, 
Rare Diseases
Intent: Curative
Funding:
ODB - General Benefit
    mercaptopurine
ODB - General Benefit
    prednisone
May 2019
Regimen
Intent: Palliative
Funding:
Exceptional Access Program
    palbociclib - For the treatment of patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER 2)-negative, unresectable locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant, according to clinical criteria
ODB - General Benefit
    letrozole
Feb 2021
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Myeloid (AML)
Intent: Curative
May 2019
Regimen
Cancer Type:
Hematologic, 
Myeloproliferative Neoplasms (MPNs)
Intent: Palliative
Funding:
ODB - General Benefit
    busulfan - oral tablets
May 2019

Pages